Benelux Price Negotiations: Beware of EU-Wide Pricing Policy, warns Germany
This article was originally published in Scrip
Executive Summary
Manufacturers could find themselves talking with multiple EU member states at once to get their orphan drugs to patients if a pilot on joint pricing negotiations is a success. Currently Belgium, the Netherlands and Luxemburg are developing the pilot, but more countries are looking at whether they may want to join in.
You may also be interested in...
"Crazy" European Orphan Drug Pricing System Has To End
Eurordis head Yann Le Cam outlines his vision for the future of orphan drug pricing in Europe.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.